Craft

Cosmo Pharmaceuticals

Stock Price

CHF69.8

2024-10-29

Market Capitalization

CHF1.1 B

2024-10-29

Revenue

€92.8 M

FY, 2023

Cosmo Pharmaceuticals Summary

Company Summary

Overview
Cosmo Pharmaceuticals is a company that focuses on solutions in the areas of gastroenterology and endoscopy. It formulates and manufactures treatments for the gastro-intestinal tract, specifically inflammatory bowel diseases (IBD), colon infections, and colon diagnosis. The company also provides a system that uses artificial intelligence to detect colorectal polyps and a medical device for the removal of colorectal lesions.
Type
Public
Status
Active
Founded
1997
HQ
Dublin, IE | view all locations
Website
https://www.cosmopharma.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Alessandro Della Chà

    Alessandro Della Chà, Executive Director, CEO

  • Luisa Bartorelli

    Luisa Bartorelli, Chief Patent Counsel

  • Dieter A. Enkelmann

    Dieter A. Enkelmann, Non-Executive Director

    • David W Maris

      David W Maris, Non-Executive Director

    Operating MetricsView all

    New Patents

    11
    10.0%

    FY, 2019

    New Trademark Families

    6
    14.3%

    FY, 2019

    Drugs in Development

    5
    25.0%

    FY, 2019

    LocationsView all

    1 location detected

    • Dublin, D HQ

      Ireland

      Riverside II, Sir John Rogerson’s Quay

    Cosmo Pharmaceuticals Financials

    Summary Financials

    Revenue (H1, 2024)
    €136.2M
    Gross profit (H1, 2024)
    €124.9M
    Net income (H1, 2024)
    €76.1M
    Cash (H1, 2024)
    €54.6M
    EBIT (H1, 2024)
    €87.0M
    Enterprise value
    $1.1B

    Footer menu